NCT01166490View on ClinicalTrials.gov

A Phase 1 Dose Escalation Trial of ASG-5ME in Pancreatic or Gastric Adenocarcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

51

Participants

Timeline

Start Date

July 31, 2010

Primary Completion Date

July 31, 2013

Study Completion Date

July 31, 2013

Conditions
Gastric NeoplasmsPancreatic Neoplasms
Interventions
DRUG

ASG-5ME

0.3-3.0 mg/kg IV on Days 1, 8, and 15 of 28-day cycles

Trial Locations (7)

75246

Texas Oncology - Baylor Sammons Cancer Center, Dallas

75702

Texas Oncology - Tyler, Tyler

85259

TGen Clinical Research Service at Scottsdale Healthcare, Scottsdale

94115

University of California at San Francisco, San Francisco

60637-1470

University of Chicago, Chicago

02215

Dana-Farber Cancer Institute, Boston

98109-1023

Seattle Cancer Care Alliance / University of Washington, Seattle

Sponsors

Collaborators (1)

Agensys, Inc.
All Listed Sponsors
collaborator

Agensys, Inc.

INDUSTRY

lead

Seagen Inc.

INDUSTRY